RE-BCG-CoV-19: BCG revaccination for healthcare workers in SARS-CoV-2 pandemic

  • Funded by European & Developing Countries Clinical Trials Partnership (EDCTP)
  • Total publications:3 publications

Grant number: RIA2020EF-2968

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    2020
  • Known Financial Commitments (USD)

    $545,000
  • Funder

    European & Developing Countries Clinical Trials Partnership (EDCTP)
  • Principle Investigator

    Pending
  • Research Location

    South Africa, Africa
  • Lead Research Institution

    Task Foundation NPC
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Health Personnel

Abstract

The RE-BCG-CoV-19 project (RIA2020EF-2968) aims to investigate whether and why BCG-revaccination can reduce infection rate and/or disease severity in healthcare workers during the SARS-CoV-2 virus disease outbreak in South Africa.

Publicationslinked via Europe PMC

Last Updated:39 minutes ago

View all publications at Europe PMC

Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic.

Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19.

Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial.